Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Mereo BioPharma Group (MREO) over the last 4 years, with Dec 2024 value amounting to $13.8 million.

  • Mereo BioPharma Group's Total Current Liabilities fell 57.66% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 57.66%. This contributed to the annual value of $13.8 million for FY2024, which is 45.98% up from last year.
  • Per Mereo BioPharma Group's latest filing, its Total Current Liabilities stood at $13.8 million for FY2024, which was up 45.98% from $9.5 million recorded in FY2023.
  • Mereo BioPharma Group's 5-year Total Current Liabilities high stood at $16.9 million for FY2021, and its period low was $9.5 million during FY2023.
  • Over the past 2 years, Mereo BioPharma Group's median Total Current Liabilities value was $11.7 million (recorded in 2023), while the average stood at $11.7 million.
  • Data for Mereo BioPharma Group's Total Current Liabilities shows a peak YoY surged of 53.70% (in 2021) over the last 5 years.
  • Over the past 4 years, Mereo BioPharma Group's Total Current Liabilities (Yearly) stood at $11.0 million in 2020, then spiked by 53.70% to $16.9 million in 2021, then reached $9.5 million in 2023, then skyrocketed by 45.98% to $13.8 million in 2024.